biostudies-literatureLiu JJapan Friendship HospitalBeijing Research Ward Construction ProgramNational High Level Hospital Clinical Research FundingElite Medical Professionals Project of Chinasfaf061https://www.ebi.ac.uk/biostudies/studies/S-EPMC11992559biostudies-literatureUnknown18(4)<h4>Background</h4>Anaemia is a common comorbidity in patients with chronic kidney disease (CKD) and heart failure (HF). Roxadustat has been approved for the treatment of anaemia in patients with CKD. However, its efficacy and safety in treating anaemia in patients with both CKD and HF remain unclear. We conducted a retrospective study with propensity score matching (PSM) to evaluate the efficacy and safety of roxadustat in this population.<h4>Methods</h4>This retrospective study enrolled patients diagnosed with HF comorbid with CKD and anaemia. The patients were divided into two groups: a roxadustat group and a control group. One-to-one PSM was used to balance baseline characteristics between the groups. The primary endpoint was the change in haemoglobin (Hb) at week 8. Secondary endpointClinical kidney journalEfficacy and safety of roxadustat for treating anaemia in patients with chronic kidney disease and heart failure: a retrospective cohort study.PMC119925592022-YJXBF-03-032022-NHLHCRF-YXHZ-012022-NHLHCRF-LX-02-0102ZRJY2021-BJ01Zhuo LZheng ZLiu JFeng LLiang YRen JYang MSu LLiu BMeng ZfalseEfficacy and safety of roxadustat for treating anaemia in patients with chronic kidney disease and heart failure: a retrospective cohort study.<h4>Background</h4>Anaemia is a common comorbidity in patients with chronic kidney disease (CKD) and heart failure (HF). Roxadustat has been approved for the treatment of anaemia in patients with CKD. However, its efficacy and safety in treating anaemia in patients with both CKD and HF remain unclear. We conducted a retrospective study with propensity score matching (PSM) to evaluate the efficacy and safety of roxadustat in this population.<h4>Methods</h4>This retrospective study enrolled patients diagnosed with HF comorbid with CKD and anaemia. The patients were divided into two groups: a roxadustat group and a control group. One-to-one PSM was used to balance baseline characteristics between the groups. The primary endpoint was the change in haemoglobin (Hb) at week 8. Secondary endpoint2025-01-01T00:00:00Z2025 Apr2026-04-08T19:08:51.253Z2025-07-13T03:06:07.106ZS-EPMC119925594022637710.1093/ckj/sfaf061